| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| AMGN - Amgen Inc | BUY | 478 @ USD 334.3 | USD 159,795 | The ETF bought 478 new shares of AMGN (Amgen Inc). The shares were bought for an average price of 334.3 compared to the previous average buy price of 292.051. This is 14.5% higher than average price of previous purchases of AMGN. |
| GILD - Guild Esports Plc | BUY | 1,218 @ USD 125.27 | USD 152,579 | The ETF bought 1218 new shares of GILD (Guild Esports Plc). The shares were bought for an average price of 125.27 compared to the previous average buy price of 113.226. This is 10.6% higher than average price of previous purchases of GILD. |
| VRTX - Vertex Pharmaceuticals Inc | BUY | 352 @ USD 424 | USD 149,248 | The ETF bought 352 new shares of VRTX (Vertex Pharmaceuticals Inc). The shares were bought for an average price of 424 compared to the previous average buy price of 438.516. This is -3.3% lower than average price of previous purchases of VRTX. |
| REGN - Regeneron Pharmaceuticals Inc | BUY | 172 @ USD 761.45 | USD 130,969 | The ETF bought 172 new shares of REGN (Regeneron Pharmaceuticals Inc). The shares were bought for an average price of 761.45 compared to the previous average buy price of 631.303. This is 20.6% higher than average price of previous purchases of REGN. |
| ALNY - Alnylam Pharmaceuticals Inc | BUY | 216 @ USD 434.23 | USD 93,794 | The ETF bought 216 new shares of ALNY (Alnylam Pharmaceuticals Inc). The shares were bought for an average price of 434.23 compared to the previous average buy price of 364.835. This is 19.0% higher than average price of previous purchases of ALNY. |
| AZN - AstraZeneca PLC | BUY | 861 @ USD 91.52 | USD 78,799 | The ETF bought 861 new shares of AZN (AstraZeneca PLC). The shares were bought for an average price of 91.52 compared to the previous average buy price of 75.3802. This is 21.4% higher than average price of previous purchases of AZN. |
| INSM - Insmed Inc | BUY | 351 @ USD 206.93 | USD 72,632 | The ETF bought 351 new shares of INSM (Insmed Inc). The shares were bought for an average price of 206.93 compared to the previous average buy price of 120.631. This is 71.5% higher than average price of previous purchases of INSM. |
| ARGX - argenx NV ADR | BUY | 51 @ USD 906.74 | USD 46,244 | The ETF bought 51 new shares of ARGX (argenx NV ADR). The shares were bought for an average price of 906.74 compared to the previous average buy price of 655.594. This is 38.3% higher than average price of previous purchases of ARGX. |
| BIIB - Biogen Inc | BUY | 244 @ USD 176.82 | USD 43,144 | The ETF bought 244 new shares of BIIB (Biogen Inc). The shares were bought for an average price of 176.82 compared to the previous average buy price of 139.958. This is 26.3% higher than average price of previous purchases of BIIB. |
| UTHR - United Therapeutics Corporation | BUY | 75 @ USD 477.2 | USD 35,790 | The ETF bought 75 new shares of UTHR (United Therapeutics Corporation). The shares were bought for an average price of 477.2 compared to the previous average buy price of 351.204. This is 35.9% higher than average price of previous purchases of UTHR. |
| INCY - Incyte Corporation | BUY | 325 @ USD 106.24 | USD 34,528 | The ETF bought 325 new shares of INCY (Incyte Corporation). The shares were bought for an average price of 106.24 compared to the previous average buy price of 75.4628. This is 40.8% higher than average price of previous purchases of INCY. |
| ILMN - Illumina Inc | BUY | 255 @ USD 125.96 | USD 32,120 | The ETF bought 255 new shares of ILMN (Illumina Inc). The shares were bought for an average price of 125.96 compared to the previous average buy price of 98.1205. This is 28.4% higher than average price of previous purchases of ILMN. |
| MEDP - Medpace Holdings Inc | BUY | 47 @ USD 618.49 | USD 29,069 | The ETF bought 47 new shares of MEDP (Medpace Holdings Inc). The shares were bought for an average price of 618.49 compared to the previous average buy price of 403.449. This is 53.3% higher than average price of previous purchases of MEDP. |
| RPRX - Royalty Pharma Plc | BUY | 717 @ USD 39.75 | USD 28,501 | The ETF bought 717 new shares of RPRX (Royalty Pharma Plc). The shares were bought for an average price of 39.75 compared to the previous average buy price of 35.7365. This is 11.2% higher than average price of previous purchases of RPRX. |
| NBIX - Neurocrine Biosciences Inc | BUY | 165 @ USD 141.25 | USD 23,306 | The ETF bought 165 new shares of NBIX (Neurocrine Biosciences Inc). The shares were bought for an average price of 141.25 compared to the previous average buy price of 130.168. This is 8.5% higher than average price of previous purchases of NBIX. |
| GH - Guardant Health Inc | BUY | 208 @ USD 111.25 | USD 23,140 | The ETF bought 208 new shares of GH (Guardant Health Inc). The shares were bought for an average price of 111.25 compared to the previous average buy price of 57.4203. This is 93.7% higher than average price of previous purchases of GH. |
| ROIV - Roivant Sciences Ltd | BUY | 1,133 @ USD 20.3 | USD 23,000 | The ETF bought 1133 new shares of ROIV (Roivant Sciences Ltd). The shares were bought for an average price of 20.3 compared to the previous average buy price of 13.3568. This is 52.0% higher than average price of previous purchases of ROIV. |
| RVMD - Revolution Medicines Inc | BUY | 312 @ USD 73.66 | USD 22,982 | The ETF bought 312 new shares of RVMD (Revolution Medicines Inc). The shares were bought for an average price of 73.66 compared to the previous average buy price of 42.8684. This is 71.8% higher than average price of previous purchases of RVMD. |
| BBIO - BridgeBio Pharma Inc | BUY | 319 @ USD 70.99 | USD 22,646 | The ETF bought 319 new shares of BBIO (BridgeBio Pharma Inc). The shares were bought for an average price of 70.99 compared to the previous average buy price of 45.7131. This is 55.3% higher than average price of previous purchases of BBIO. |
| SMMT - Summit Therapeutics PLC | BUY | 1,237 @ USD 17.84 | USD 22,068 | The ETF bought 1237 new shares of SMMT (Summit Therapeutics PLC). The shares were bought for an average price of 17.84 compared to the previous average buy price of 21.0548. This is -15.3% lower than average price of previous purchases of SMMT. |
| SNY - Sanofi ADR | BUY | 447 @ USD 49.15 | USD 21,970 | The ETF bought 447 new shares of SNY (Sanofi ADR). The shares were bought for an average price of 49.15 compared to the previous average buy price of 50.0832. This is -1.9% lower than average price of previous purchases of SNY. |
| MDGL - Madrigal Pharmaceuticals Inc | BUY | 37 @ USD 587.92 | USD 21,753 | The ETF bought 37 new shares of MDGL (Madrigal Pharmaceuticals Inc). The shares were bought for an average price of 587.92 compared to the previous average buy price of 359.336. This is 63.6% higher than average price of previous purchases of MDGL. |
| ASND - Ascendis Pharma AS | BUY | 101 @ USD 209.03 | USD 21,112 | The ETF bought 101 new shares of ASND (Ascendis Pharma AS). The shares were bought for an average price of 209.03 compared to the previous average buy price of 179.974. This is 16.1% higher than average price of previous purchases of ASND. |
| IONS - Ionis Pharmaceuticals Inc | BUY | 266 @ USD 78.52 | USD 20,886 | The ETF bought 266 new shares of IONS (Ionis Pharmaceuticals Inc). The shares were bought for an average price of 78.52 compared to the previous average buy price of 49.6027. This is 58.3% higher than average price of previous purchases of IONS. |
| VTRS - Viatris Inc | BUY | 1,945 @ USD 10.57 | USD 20,559 | The ETF bought 1945 new shares of VTRS (Viatris Inc). The shares were bought for an average price of 10.57 compared to the previous average buy price of 9.65148. This is 9.5% higher than average price of previous purchases of VTRS. |
| EXEL - Exelixis Inc | BUY | 447 @ USD 42.25 | USD 18,886 | The ETF bought 447 new shares of EXEL (Exelixis Inc). The shares were bought for an average price of 42.25 compared to the previous average buy price of 41.0591. This is 2.9% higher than average price of previous purchases of EXEL. |
| JAZZ - Jazz Pharmaceuticals PLC | BUY | 101 @ USD 180.9 | USD 18,271 | The ETF bought 101 new shares of JAZZ (Jazz Pharmaceuticals PLC). The shares were bought for an average price of 180.9 compared to the previous average buy price of 124.943. This is 44.8% higher than average price of previous purchases of JAZZ. |
| BMRN - Biomarin Pharmaceutical Inc | BUY | 318 @ USD 55.5 | USD 17,649 | The ETF bought 318 new shares of BMRN (Biomarin Pharmaceutical Inc). The shares were bought for an average price of 55.5 compared to the previous average buy price of 57.9959. This is -4.3% lower than average price of previous purchases of BMRN. |
| BNTX - BioNTech SE | BUY | 167 @ USD 96.54 | USD 16,122 | The ETF bought 167 new shares of BNTX (BioNTech SE). The shares were bought for an average price of 96.54 compared to the previous average buy price of 104.946. This is -8.0% lower than average price of previous purchases of BNTX. |
| MRNA - Moderna Inc | BUY | 646 @ USD 24.15 | USD 15,601 | The ETF bought 646 new shares of MRNA (Moderna Inc). The shares were bought for an average price of 24.15 compared to the previous average buy price of 28.8504. This is -16.3% lower than average price of previous purchases of MRNA. |
| RNA - Avidity Biosciences Inc | BUY | 213 @ USD 71.2 | USD 15,166 | The ETF bought 213 new shares of RNA (Avidity Biosciences Inc). The shares were bought for an average price of 71.2 compared to the previous average buy price of 38.7375. This is 83.8% higher than average price of previous purchases of RNA. |
| HALO - Halozyme Therapeutics Inc | BUY | 194 @ USD 74 | USD 14,356 | The ETF bought 194 new shares of HALO (Halozyme Therapeutics Inc). The shares were bought for an average price of 74 compared to the previous average buy price of 60.3545. This is 22.6% higher than average price of previous purchases of HALO. |
| CYTK - Cytokinetics Inc | BUY | 198 @ USD 67.21 | USD 13,308 | The ETF bought 198 new shares of CYTK (Cytokinetics Inc). The shares were bought for an average price of 67.21 compared to the previous average buy price of 44.1373. This is 52.3% higher than average price of previous purchases of CYTK. |
| AXSM - Axsome Therapeutics Inc | BUY | 83 @ USD 151.2 | USD 12,550 | The ETF bought 83 new shares of AXSM (Axsome Therapeutics Inc). The shares were bought for an average price of 151.2 compared to the previous average buy price of 116.625. This is 29.6% higher than average price of previous purchases of AXSM. |
| NUVL - Nuvalent Inc | BUY | 111 @ USD 109.53 | USD 12,158 | The ETF bought 111 new shares of NUVL (Nuvalent Inc). The shares were bought for an average price of 109.53 compared to the previous average buy price of 83.2658. This is 31.5% higher than average price of previous purchases of NUVL. |
| MRUS - Merus BV | BUY | 126 @ USD 95.95 | USD 12,090 | The ETF bought 126 new shares of MRUS (Merus BV). The shares were bought for an average price of 95.95 compared to the previous average buy price of 65.3714. This is 46.8% higher than average price of previous purchases of MRUS. |
| RYTM - Rhythm Pharmaceuticals Inc | BUY | 111 @ USD 106.58 | USD 11,830 | The ETF bought 111 new shares of RYTM (Rhythm Pharmaceuticals Inc). The shares were bought for an average price of 106.58 compared to the previous average buy price of 76.8775. This is 38.6% higher than average price of previous purchases of RYTM. |
| PCVX - Vaxcyte Inc | BUY | 216 @ USD 49.25 | USD 10,638 | The ETF bought 216 new shares of PCVX (Vaxcyte Inc). The shares were bought for an average price of 49.25 compared to the previous average buy price of 44.9857. This is 9.5% higher than average price of previous purchases of PCVX. |
| PTCT - PTC Therapeutics Inc | BUY | 132 @ USD 79.83 | USD 10,538 | The ETF bought 132 new shares of PTCT (PTC Therapeutics Inc). The shares were bought for an average price of 79.83 compared to the previous average buy price of 56.0103. This is 42.5% higher than average price of previous purchases of PTCT. |
| KRYS - Krystal Biotech Inc | BUY | 48 @ USD 214.89 | USD 10,315 | The ETF bought 48 new shares of KRYS (Krystal Biotech Inc). The shares were bought for an average price of 214.89 compared to the previous average buy price of 163.223. This is 31.7% higher than average price of previous purchases of KRYS. |
| ARWR - Arrowhead Pharmaceuticals Inc | BUY | 230 @ USD 44.26 | USD 10,180 | The ETF bought 230 new shares of ARWR (Arrowhead Pharmaceuticals Inc). The shares were bought for an average price of 44.26 compared to the previous average buy price of 22.1661. This is 99.7% higher than average price of previous purchases of ARWR. |
| PTGX - Protagonist Therapeutics Inc | BUY | 104 @ USD 87.69 | USD 9,120 | The ETF bought 104 new shares of PTGX (Protagonist Therapeutics Inc). The shares were bought for an average price of 87.69 compared to the previous average buy price of 58.0316. This is 51.1% higher than average price of previous purchases of PTGX. |
| COGT - Cogent Biosciences Inc | BUY | 230 @ USD 38.54 | USD 8,864 | The ETF bought 230 new shares of COGT (Cogent Biosciences Inc). The shares were bought for an average price of 38.54 compared to the previous average buy price of 11.6306. This is 231.4% higher than average price of previous purchases of COGT. |
| KYMR - Kymera Therapeutics Inc | BUY | 119 @ USD 65.59 | USD 7,805 | The ETF bought 119 new shares of KYMR (Kymera Therapeutics Inc). The shares were bought for an average price of 65.59 compared to the previous average buy price of 47.1574. This is 39.1% higher than average price of previous purchases of KYMR. |
| ALKS - Alkermes Plc | BUY | 275 @ USD 28.2 | USD 7,755 | The ETF bought 275 new shares of ALKS (Alkermes Plc). The shares were bought for an average price of 28.2 compared to the previous average buy price of 30.3665. This is -7.1% lower than average price of previous purchases of ALKS. |
| CRSP - Crispr Therapeutics AG | BUY | 151 @ USD 51.25 | USD 7,739 | The ETF bought 151 new shares of CRSP (Crispr Therapeutics AG). The shares were bought for an average price of 51.25 compared to the previous average buy price of 52.4269. This is -2.2% lower than average price of previous purchases of CRSP. |
| ADMA - ADMA Biologics Inc | BUY | 400 @ USD 18.32 | USD 7,328 | The ETF bought 400 new shares of ADMA (ADMA Biologics Inc). The shares were bought for an average price of 18.32 compared to the previous average buy price of 17.2641. This is 6.1% higher than average price of previous purchases of ADMA. |
| AKRO - Akero Therapeutics Inc | BUY | 133 @ USD 54.36 | USD 7,230 | The ETF bought 133 new shares of AKRO (Akero Therapeutics Inc). The shares were bought for an average price of 54.36 compared to the previous average buy price of 49.5322. This is 9.7% higher than average price of previous purchases of AKRO. |
| ACLX - Arcellx Inc | BUY | 92 @ USD 74.96 | USD 6,896 | The ETF bought 92 new shares of ACLX (Arcellx Inc). The shares were bought for an average price of 74.96 compared to the previous average buy price of 72.9389. This is 2.8% higher than average price of previous purchases of ACLX. |
| CRNX - Crinetics Pharmaceuticals Inc | BUY | 157 @ USD 43.84 | USD 6,883 | The ETF bought 157 new shares of CRNX (Crinetics Pharmaceuticals Inc). The shares were bought for an average price of 43.84 compared to the previous average buy price of 35.4621. This is 23.6% higher than average price of previous purchases of CRNX. |
| IMVT - Immunovant Inc | BUY | 293 @ USD 23.32 | USD 6,833 | The ETF bought 293 new shares of IMVT (Immunovant Inc). The shares were bought for an average price of 23.32 compared to the previous average buy price of 18.2839. This is 27.5% higher than average price of previous purchases of IMVT. |
| LGND - Ligand Pharmaceuticals Incorporated | BUY | 33 @ USD 206.89 | USD 6,827 | The ETF bought 33 new shares of LGND (Ligand Pharmaceuticals Incorporated). The shares were bought for an average price of 206.89 compared to the previous average buy price of 136.964. This is 51.1% higher than average price of previous purchases of LGND. |
| ACAD - ACADIA Pharmaceuticals Inc | BUY | 283 @ USD 23.9 | USD 6,764 | The ETF bought 283 new shares of ACAD (ACADIA Pharmaceuticals Inc). The shares were bought for an average price of 23.9 compared to the previous average buy price of 20.9948. This is 13.8% higher than average price of previous purchases of ACAD. |
| SRRK - Scholar Rock Holding Corp | BUY | 161 @ USD 41.79 | USD 6,728 | The ETF bought 161 new shares of SRRK (Scholar Rock Holding Corp). The shares were bought for an average price of 41.79 compared to the previous average buy price of 35.1192. This is 19.0% higher than average price of previous purchases of SRRK. |
| GRAL - GRAIL, LLC | BUY | 60 @ USD 111.4 | USD 6,684 | The ETF bought 60 new shares of GRAL (GRAIL, LLC). The shares were bought for an average price of 111.4 compared to the previous average buy price of 54.2375. This is 105.4% higher than average price of previous purchases of GRAL. |
| PRAX - Praxis Precision Medicines Inc | BUY | 35 @ USD 190.855 | USD 6,680 | The ETF bought 35 new shares of PRAX (Praxis Precision Medicines Inc). The shares were bought for an average price of 190.855 compared to the previous average buy price of 68.442. This is 178.9% higher than average price of previous purchases of PRAX. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | BUY | 528 @ USD 12.15 | USD 6,415 | The ETF bought 528 new shares of AMRX (Amneal Pharmaceuticals, Inc. Class A Common Stock). The shares were bought for an average price of 12.15 compared to the previous average buy price of 8.96212. This is 35.6% higher than average price of previous purchases of AMRX. |
| VCYT - Veracyte Inc | BUY | 132 @ USD 46.7 | USD 6,164 | The ETF bought 132 new shares of VCYT (Veracyte Inc). The shares were bought for an average price of 46.7 compared to the previous average buy price of 31.7414. This is 47.1% higher than average price of previous purchases of VCYT. |
| ARQT - Arcutis Biotherapeutics Inc | BUY | 198 @ USD 30.76 | USD 6,090 | The ETF bought 198 new shares of ARQT (Arcutis Biotherapeutics Inc). The shares were bought for an average price of 30.76 compared to the previous average buy price of 16.8117. This is 83.0% higher than average price of previous purchases of ARQT. |
| MIRM - Mirum Pharmaceuticals Inc | BUY | 84 @ USD 72.2 | USD 6,065 | The ETF bought 84 new shares of MIRM (Mirum Pharmaceuticals Inc). The shares were bought for an average price of 72.2 compared to the previous average buy price of 56.3701. This is 28.1% higher than average price of previous purchases of MIRM. |
| TARS - Tarsus Pharmaceuticals Inc | BUY | 71 @ USD 82.11 | USD 5,830 | The ETF bought 71 new shares of TARS (Tarsus Pharmaceuticals Inc). The shares were bought for an average price of 82.11 compared to the previous average buy price of 50.5753. This is 62.4% higher than average price of previous purchases of TARS. |
| CGON - CG Oncology, Inc. Common stock | BUY | 128 @ USD 43.56 | USD 5,576 | The ETF bought 128 new shares of CGON (CG Oncology, Inc. Common stock). The shares were bought for an average price of 43.56 compared to the previous average buy price of 30.5605. This is 42.5% higher than average price of previous purchases of CGON. |
| IRON - Ironveld Plc | BUY | 58 @ USD 94.11 | USD 5,458 | The ETF bought 58 new shares of IRON (Ironveld Plc). The shares were bought for an average price of 94.11 compared to the previous average buy price of 60.1958. This is 56.3% higher than average price of previous purchases of IRON. |
| XENE - Xenon Pharmaceuticals Inc | BUY | 129 @ USD 42.05 | USD 5,424 | The ETF bought 129 new shares of XENE (Xenon Pharmaceuticals Inc). The shares were bought for an average price of 42.05 compared to the previous average buy price of 35.9088. This is 17.1% higher than average price of previous purchases of XENE. |
| RARE - Ultragenyx | BUY | 162 @ USD 32.78 | USD 5,310 | The ETF bought 162 new shares of RARE (Ultragenyx). The shares were bought for an average price of 32.78 compared to the previous average buy price of 36.2808. This is -9.6% lower than average price of previous purchases of RARE. |
| RARE - WISETFWTMRARETFP | BUY | 162 @ USD 32.78 | USD 5,310 | The ETF bought 162 new shares of RARE (WISETFWTMRARETFP). The shares were bought for an average price of 32.78 compared to the previous average buy price of 36.2808. This is -9.6% lower than average price of previous purchases of RARE. |
| TVTX - Travere Therapeutics Inc | BUY | 147 @ USD 35.79 | USD 5,261 | The ETF bought 147 new shares of TVTX (Travere Therapeutics Inc). The shares were bought for an average price of 35.79 compared to the previous average buy price of 20.6703. This is 73.1% higher than average price of previous purchases of TVTX. |
| DYN - Dyne Therapeutics Inc | BUY | 239 @ USD 21.67 | USD 5,179 | The ETF bought 239 new shares of DYN (Dyne Therapeutics Inc). The shares were bought for an average price of 21.67 compared to the previous average buy price of 13.2417. This is 63.6% higher than average price of previous purchases of DYN. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | BUY | 239 @ USD 21.67 | USD 5,179 | The ETF bought 239 new shares of DYN (DYNAGREEN EN.PR.GR.H YC 1). The shares were bought for an average price of 21.67 compared to the previous average buy price of 13.2417. This is 63.6% higher than average price of previous purchases of DYN. |
| APGE - Apogee Therapeutics, Inc. Common Stock | BUY | 76 @ USD 67.85 | USD 5,157 | The ETF bought 76 new shares of APGE (Apogee Therapeutics, Inc. Common Stock). The shares were bought for an average price of 67.85 compared to the previous average buy price of 44.9769. This is 50.9% higher than average price of previous purchases of APGE. |
| ADPT - Adaptive Biotechnologies Corp | BUY | 252 @ USD 20.46 | USD 5,156 | The ETF bought 252 new shares of ADPT (Adaptive Biotechnologies Corp). The shares were bought for an average price of 20.46 compared to the previous average buy price of 11.9977. This is 70.5% higher than average price of previous purchases of ADPT. |
| IDYA - Ideaya Biosciences Inc | BUY | 148 @ USD 34.67 | USD 5,131 | The ETF bought 148 new shares of IDYA (Ideaya Biosciences Inc). The shares were bought for an average price of 34.67 compared to the previous average buy price of 23.8221. This is 45.5% higher than average price of previous purchases of IDYA. |
| FOLD - Amicus Therapeutics Inc | BUY | 510 @ USD 9.89 | USD 5,044 | The ETF bought 510 new shares of FOLD (Amicus Therapeutics Inc). The shares were bought for an average price of 9.89 compared to the previous average buy price of 7.4929. This is 32.0% higher than average price of previous purchases of FOLD. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | BUY | 109 @ USD 42.6 | USD 4,643 | The ETF bought 109 new shares of MLYS (Mineralys Therapeutics, Inc. Common Stock). The shares were bought for an average price of 42.6 compared to the previous average buy price of 20.7569. This is 105.2% higher than average price of previous purchases of MLYS. |
| CNTA - Centessa Pharmaceuticals PLC ADR | BUY | 158 @ USD 29.37 | USD 4,640 | The ETF bought 158 new shares of CNTA (Centessa Pharmaceuticals PLC ADR). The shares were bought for an average price of 29.37 compared to the previous average buy price of 16.9879. This is 72.9% higher than average price of previous purchases of CNTA. |
| DNLI - Denali Therapeutics Inc | BUY | 242 @ USD 18.93 | USD 4,581 | The ETF bought 242 new shares of DNLI (Denali Therapeutics Inc). The shares were bought for an average price of 18.93 compared to the previous average buy price of 15.2856. This is 23.8% higher than average price of previous purchases of DNLI. |
| APLS - Apellis Pharmaceuticals Inc | BUY | 212 @ USD 20.13 | USD 4,268 | The ETF bought 212 new shares of APLS (Apellis Pharmaceuticals Inc). The shares were bought for an average price of 20.13 compared to the previous average buy price of 21.014. This is -4.2% lower than average price of previous purchases of APLS. |
| SUPN - Supernus Pharmaceuticals Inc | BUY | 94 @ USD 45.15 | USD 4,244 | The ETF bought 94 new shares of SUPN (Supernus Pharmaceuticals Inc). The shares were bought for an average price of 45.15 compared to the previous average buy price of 38.0124. This is 18.8% higher than average price of previous purchases of SUPN. |
| EWTX - Edgewise Therapeutics Inc | BUY | 174 @ USD 23.48 | USD 4,086 | The ETF bought 174 new shares of EWTX (Edgewise Therapeutics Inc). The shares were bought for an average price of 23.48 compared to the previous average buy price of 16.2189. This is 44.8% higher than average price of previous purchases of EWTX. |
| TERN - Tern Plc | BUY | 145 @ USD 28.04 | USD 4,066 | The ETF bought 145 new shares of TERN (Tern Plc). The shares were bought for an average price of 28.04 compared to the previous average buy price of 6.3794. This is 339.5% higher than average price of previous purchases of TERN. |
| BEAM - Beam Therapeutics Inc | BUY | 167 @ USD 23.62 | USD 3,945 | The ETF bought 167 new shares of BEAM (Beam Therapeutics Inc). The shares were bought for an average price of 23.62 compared to the previous average buy price of 20.6305. This is 14.5% higher than average price of previous purchases of BEAM. |
| TXG - 10X Genomics Inc | BUY | 192 @ USD 20.13 | USD 3,865 | The ETF bought 192 new shares of TXG (10X Genomics Inc). The shares were bought for an average price of 20.13 compared to the previous average buy price of 12.2699. This is 64.1% higher than average price of previous purchases of TXG. |
| TXG - Terex Corporation | BUY | 192 @ USD 20.13 | USD 3,865 | The ETF bought 192 new shares of TXG (Terex Corporation). The shares were bought for an average price of 20.13 compared to the previous average buy price of 12.2699. This is 64.1% higher than average price of previous purchases of TXG. |
| LEGN - Legend Biotech Corp | BUY | 140 @ USD 27.15 | USD 3,801 | The ETF bought 140 new shares of LEGN (Legend Biotech Corp). The shares were bought for an average price of 27.15 compared to the previous average buy price of 34.3024. This is -20.9% lower than average price of previous purchases of LEGN. |
| AVDL - Avadel Pharmaceuticals PLC | BUY | 161 @ USD 22.92 | USD 3,690 | The ETF bought 161 new shares of AVDL (Avadel Pharmaceuticals PLC). The shares were bought for an average price of 22.92 compared to the previous average buy price of 11.5749. This is 98.0% higher than average price of previous purchases of AVDL. |
| AUPH - Aurinia Pharmaceuticals Inc | BUY | 218 @ USD 16.11 | USD 3,512 | The ETF bought 218 new shares of AUPH (Aurinia Pharmaceuticals Inc). The shares were bought for an average price of 16.11 compared to the previous average buy price of 9.54325. This is 68.8% higher than average price of previous purchases of AUPH. |
| OCUL - Ocular Therapeutix Inc | BUY | 288 @ USD 12.1 | USD 3,485 | The ETF bought 288 new shares of OCUL (Ocular Therapeutix Inc). The shares were bought for an average price of 12.1 compared to the previous average buy price of 9.76508. This is 23.9% higher than average price of previous purchases of OCUL. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | BUY | 98 @ USD 35.3 | USD 3,459 | The ETF bought 98 new shares of GPCR (Structure Therapeutics Inc. American Depositary Shares). The shares were bought for an average price of 35.3 compared to the previous average buy price of 23.8806. This is 47.8% higher than average price of previous purchases of GPCR. |
| IBRX - Immunitybio Inc | BUY | 1,593 @ USD 2.15 | USD 3,425 | The ETF bought 1593 new shares of IBRX (Immunitybio Inc). The shares were bought for an average price of 2.15 compared to the previous average buy price of 2.73295. This is -21.3% lower than average price of previous purchases of IBRX. |
| HRMY - Harmony Biosciences Holdings | BUY | 95 @ USD 35.27 | USD 3,351 | The ETF bought 95 new shares of HRMY (Harmony Biosciences Holdings). The shares were bought for an average price of 35.27 compared to the previous average buy price of 31.8774. This is 10.6% higher than average price of previous purchases of HRMY. |
| VCEL - Vericel Corp Ord | BUY | 83 @ USD 38.88 | USD 3,227 | The ETF bought 83 new shares of VCEL (Vericel Corp Ord). The shares were bought for an average price of 38.88 compared to the previous average buy price of 40.7191. This is -4.5% lower than average price of previous purchases of VCEL. |
| ZYME - Zymeworks Inc. Common Stock | BUY | 128 @ USD 24.99 | USD 3,199 | The ETF bought 128 new shares of ZYME (Zymeworks Inc. Common Stock). The shares were bought for an average price of 24.99 compared to the previous average buy price of 14.8295. This is 68.5% higher than average price of previous purchases of ZYME. |
| RXRX - Recursion Pharmaceuticals Inc | BUY | 723 @ USD 4.33 | USD 3,131 | The ETF bought 723 new shares of RXRX (Recursion Pharmaceuticals Inc). The shares were bought for an average price of 4.33 compared to the previous average buy price of 5.70893. This is -24.2% lower than average price of previous purchases of RXRX. |
| JANX - Janux Therapeutics Inc | BUY | 99 @ USD 31.53 | USD 3,121 | The ETF bought 99 new shares of JANX (Janux Therapeutics Inc). The shares were bought for an average price of 31.53 compared to the previous average buy price of 27.7821. This is 13.5% higher than average price of previous purchases of JANX. |
| VERA - Vera Therapeutics Inc | BUY | 106 @ USD 29.24 | USD 3,099 | The ETF bought 106 new shares of VERA (Vera Therapeutics Inc). The shares were bought for an average price of 29.24 compared to the previous average buy price of 27.0558. This is 8.1% higher than average price of previous purchases of VERA. |
| KNSA - Kiniksa Pharmaceuticals Ltd | BUY | 73 @ USD 41.97 | USD 3,064 | The ETF bought 73 new shares of KNSA (Kiniksa Pharmaceuticals Ltd). The shares were bought for an average price of 41.97 compared to the previous average buy price of 30.4379. This is 37.9% higher than average price of previous purchases of KNSA. |
| SRPT - Sarepta Therapeutics Inc | BUY | 162 @ USD 18.91 | USD 3,063 | The ETF bought 162 new shares of SRPT (Sarepta Therapeutics Inc). The shares were bought for an average price of 18.91 compared to the previous average buy price of 33.4721. This is -43.5% lower than average price of previous purchases of SRPT. |
| TWST - Twist Bioscience Corp | BUY | 100 @ USD 29.33 | USD 2,933 | The ETF bought 100 new shares of TWST (Twist Bioscience Corp). The shares were bought for an average price of 29.33 compared to the previous average buy price of 35.7622. This is -18.0% lower than average price of previous purchases of TWST. |
| ANIP - ANI Pharmaceuticals Inc | BUY | 36 @ USD 80.98 | USD 2,915 | The ETF bought 36 new shares of ANIP (ANI Pharmaceuticals Inc). The shares were bought for an average price of 80.98 compared to the previous average buy price of 73.1537. This is 10.7% higher than average price of previous purchases of ANIP. |
| SNDX - Syndax Pharmaceuticals Inc | BUY | 143 @ USD 19.76 | USD 2,826 | The ETF bought 143 new shares of SNDX (Syndax Pharmaceuticals Inc). The shares were bought for an average price of 19.76 compared to the previous average buy price of 11.9828. This is 64.9% higher than average price of previous purchases of SNDX. |
| STOK - Stoke Therapeutics Inc | BUY | 93 @ USD 30.34 | USD 2,822 | The ETF bought 93 new shares of STOK (Stoke Therapeutics Inc). The shares were bought for an average price of 30.34 compared to the previous average buy price of 16.5553. This is 83.3% higher than average price of previous purchases of STOK. |
| OLMA - Olema Pharmaceuticals Inc | BUY | 112 @ USD 25.05 | USD 2,806 | The ETF bought 112 new shares of OLMA (Olema Pharmaceuticals Inc). The shares were bought for an average price of 25.05 compared to the previous average buy price of 6.04545. This is 314.4% higher than average price of previous purchases of OLMA. |
| SYRE - Spyre Therapeutics Inc. | BUY | 100 @ USD 26.97 | USD 2,697 | The ETF bought 100 new shares of SYRE (Spyre Therapeutics Inc.). The shares were bought for an average price of 26.97 compared to the previous average buy price of 17.8519. This is 51.1% higher than average price of previous purchases of SYRE. |
| IMCR - Immunocore Holdings Ltd | BUY | 68 @ USD 38.69 | USD 2,631 | The ETF bought 68 new shares of IMCR (Immunocore Holdings Ltd). The shares were bought for an average price of 38.69 compared to the previous average buy price of 32.9774. This is 17.3% higher than average price of previous purchases of IMCR. |
| MNKD - MannKind Corp | BUY | 511 @ USD 5.13 | USD 2,621 | The ETF bought 511 new shares of MNKD (MannKind Corp). The shares were bought for an average price of 5.13 compared to the previous average buy price of 4.75929. This is 7.8% higher than average price of previous purchases of MNKD. |
| QURE - Uniqure NV | BUY | 92 @ USD 27.78 | USD 2,556 | The ETF bought 92 new shares of QURE (Uniqure NV). The shares were bought for an average price of 27.78 compared to the previous average buy price of 23.4577. This is 18.4% higher than average price of previous purchases of QURE. |
| AGIO - Agios Pharm | BUY | 96 @ USD 26.49 | USD 2,543 | The ETF bought 96 new shares of AGIO (Agios Pharm). The shares were bought for an average price of 26.49 compared to the previous average buy price of 36.3318. This is -27.1% lower than average price of previous purchases of AGIO. |
| BCRX - BioCryst Pharmaceuticals Inc | BUY | 350 @ USD 6.83 | USD 2,391 | The ETF bought 350 new shares of BCRX (BioCryst Pharmaceuticals Inc). The shares were bought for an average price of 6.83 compared to the previous average buy price of 8.24688. This is -17.2% lower than average price of previous purchases of BCRX. |
| HROW - Harrow Health Inc | BUY | 61 @ USD 39 | USD 2,379 | The ETF bought 61 new shares of HROW (Harrow Health Inc). The shares were bought for an average price of 39 compared to the previous average buy price of 33.707. This is 15.7% higher than average price of previous purchases of HROW. |
| COLL - Collegium Pharmaceutical Inc | BUY | 52 @ USD 45.575 | USD 2,370 | The ETF bought 52 new shares of COLL (Collegium Pharmaceutical Inc). The shares were bought for an average price of 45.575 compared to the previous average buy price of 32.3928. This is 40.7% higher than average price of previous purchases of COLL. |
| NVCR - Novocure Ltd | BUY | 186 @ USD 12.53 | USD 2,331 | The ETF bought 186 new shares of NVCR (Novocure Ltd). The shares were bought for an average price of 12.53 compared to the previous average buy price of 16.5053. This is -24.1% lower than average price of previous purchases of NVCR. |
| NRIX - Nurix Therapeutics Inc | BUY | 134 @ USD 17.15 | USD 2,298 | The ETF bought 134 new shares of NRIX (Nurix Therapeutics Inc). The shares were bought for an average price of 17.15 compared to the previous average buy price of 12.0948. This is 41.8% higher than average price of previous purchases of NRIX. |
| DVAX - Dynavax Technologies Corporation | BUY | 195 @ USD 11.44 | USD 2,231 | The ETF bought 195 new shares of DVAX (Dynavax Technologies Corporation). The shares were bought for an average price of 11.44 compared to the previous average buy price of 10.4874. This is 9.1% higher than average price of previous purchases of DVAX. |
| INVA - Innoviva Inc | BUY | 104 @ USD 21.29 | USD 2,214 | The ETF bought 104 new shares of INVA (Innoviva Inc). The shares were bought for an average price of 21.29 compared to the previous average buy price of 19.0967. This is 11.5% higher than average price of previous purchases of INVA. |
| ARDX - Ardelyx Inc | BUY | 402 @ USD 5.5 | USD 2,211 | The ETF bought 402 new shares of ARDX (Ardelyx Inc). The shares were bought for an average price of 5.5 compared to the previous average buy price of 4.68368. This is 17.4% higher than average price of previous purchases of ARDX. |
| AMLX - Amylyx Pharmaceuticals Inc | BUY | 148 @ USD 14.82 | USD 2,193 | The ETF bought 148 new shares of AMLX (Amylyx Pharmaceuticals Inc). The shares were bought for an average price of 14.82 compared to the previous average buy price of 7.21452. This is 105.4% higher than average price of previous purchases of AMLX. |
| GMAB - Genmab AS | BUY | 70 @ USD 30.82 | USD 2,157 | The ETF bought 70 new shares of GMAB (Genmab AS). The shares were bought for an average price of 30.82 compared to the previous average buy price of 23.8028. This is 29.5% higher than average price of previous purchases of GMAB. |
| URGN - UroGen Pharma Ltd | BUY | 80 @ USD 26.93 | USD 2,154 | The ETF bought 80 new shares of URGN (UroGen Pharma Ltd). The shares were bought for an average price of 26.93 compared to the previous average buy price of 15.061. This is 78.8% higher than average price of previous purchases of URGN. |
| ELVN - Enliven Therapeutics Inc. | BUY | 98 @ USD 21.77 | USD 2,133 | The ETF bought 98 new shares of ELVN (Enliven Therapeutics Inc.). The shares were bought for an average price of 21.77 compared to the previous average buy price of 20.9164. This is 4.1% higher than average price of previous purchases of ELVN. |
| AMPH - Amphastar P | BUY | 77 @ USD 26.71 | USD 2,057 | The ETF bought 77 new shares of AMPH (Amphastar P). The shares were bought for an average price of 26.71 compared to the previous average buy price of 25.6173. This is 4.3% higher than average price of previous purchases of AMPH. |
| WVE - Wave Life Sciences Ltd | BUY | 272 @ USD 7.46 | USD 2,029 | The ETF bought 272 new shares of WVE (Wave Life Sciences Ltd). The shares were bought for an average price of 7.46 compared to the previous average buy price of 8.38182. This is -11.0% lower than average price of previous purchases of WVE. |
| TSHA - Taysha Gene Therapies Inc | BUY | 456 @ USD 4.42 | USD 2,016 | The ETF bought 456 new shares of TSHA (Taysha Gene Therapies Inc). The shares were bought for an average price of 4.42 compared to the previous average buy price of 2.93294. This is 50.7% higher than average price of previous purchases of TSHA. |
| XNCR - Xencor Inc | BUY | 119 @ USD 16.74 | USD 1,992 | The ETF bought 119 new shares of XNCR (Xencor Inc). The shares were bought for an average price of 16.74 compared to the previous average buy price of 11.4219. This is 46.6% higher than average price of previous purchases of XNCR. |
| XERS - Xeris Pharmaceuticals Inc | BUY | 278 @ USD 7.04 | USD 1,957 | The ETF bought 278 new shares of XERS (Xeris Pharmaceuticals Inc). The shares were bought for an average price of 7.04 compared to the previous average buy price of 6.12494. This is 14.9% higher than average price of previous purchases of XERS. |
| PGEN - Precigen Inc | BUY | 509 @ USD 3.82 | USD 1,944 | The ETF bought 509 new shares of PGEN (Precigen Inc). The shares were bought for an average price of 3.82 compared to the previous average buy price of 2.4309. This is 57.1% higher than average price of previous purchases of PGEN. |
| ANAB - AnaptysBio Inc | BUY | 46 @ USD 41.95 | USD 1,930 | The ETF bought 46 new shares of ANAB (AnaptysBio Inc). The shares were bought for an average price of 41.95 compared to the previous average buy price of 24.6732. This is 70.0% higher than average price of previous purchases of ANAB. |
| TNGX - Tango Therapeutics Inc | BUY | 186 @ USD 10.33 | USD 1,921 | The ETF bought 186 new shares of TNGX (Tango Therapeutics Inc). The shares were bought for an average price of 10.33 compared to the previous average buy price of 6.28477. This is 64.4% higher than average price of previous purchases of TNGX. |
| CVAC - CureVac NV | BUY | 376 @ USD 5.11 | USD 1,921 | The ETF bought 376 new shares of CVAC (CureVac NV). The shares were bought for an average price of 5.11 compared to the previous average buy price of 4.84586. This is 5.5% higher than average price of previous purchases of CVAC. |
| ORIC - Oric Pharmaceuticals Inc | BUY | 162 @ USD 11.79 | USD 1,910 | The ETF bought 162 new shares of ORIC (Oric Pharmaceuticals Inc). The shares were bought for an average price of 11.79 compared to the previous average buy price of 10.5899. This is 11.3% higher than average price of previous purchases of ORIC. |
| CSTL - Castle Biosciences Inc | BUY | 48 @ USD 38.49 | USD 1,848 | The ETF bought 48 new shares of CSTL (Castle Biosciences Inc). The shares were bought for an average price of 38.49 compared to the previous average buy price of 22.447. This is 71.5% higher than average price of previous purchases of CSTL. |
| FTRE - Fortrea Holdings Inc. | BUY | 152 @ USD 11.95 | USD 1,816 | The ETF bought 152 new shares of FTRE (Fortrea Holdings Inc.). The shares were bought for an average price of 11.95 compared to the previous average buy price of 6.89078. This is 73.4% higher than average price of previous purchases of FTRE. |
| NVAX - Novavax Inc | BUY | 272 @ USD 6.63 | USD 1,803 | The ETF bought 272 new shares of NVAX (Novavax Inc). The shares were bought for an average price of 6.63 compared to the previous average buy price of 7.35979. This is -9.9% lower than average price of previous purchases of NVAX. |
| NVAX - Hana Microelectronics Public Company Limited | BUY | 272 @ USD 6.63 | USD 1,803 | The ETF bought 272 new shares of NVAX (Hana Microelectronics Public Company Limited). The shares were bought for an average price of 6.63 compared to the previous average buy price of 7.35979. This is -9.9% lower than average price of previous purchases of NVAX. |
| PHAT - Phathom Pharmaceuticals Inc | BUY | 121 @ USD 14.82 | USD 1,793 | The ETF bought 121 new shares of PHAT (Phathom Pharmaceuticals Inc). The shares were bought for an average price of 14.82 compared to the previous average buy price of 9.31123. This is 59.2% higher than average price of previous purchases of PHAT. |
| ABCL - Abcellera Biologics Inc | BUY | 500 @ USD 3.57 | USD 1,785 | The ETF bought 500 new shares of ABCL (Abcellera Biologics Inc). The shares were bought for an average price of 3.57 compared to the previous average buy price of 3.89547. This is -8.4% lower than average price of previous purchases of ABCL. |
| KURA - Kura Oncology Inc | BUY | 151 @ USD 11.73 | USD 1,771 | The ETF bought 151 new shares of KURA (Kura Oncology Inc). The shares were bought for an average price of 11.73 compared to the previous average buy price of 7.46164. This is 57.2% higher than average price of previous purchases of KURA. |
| PCRX - Pacira BioSciences, Inc. | BUY | 75 @ USD 23.16 | USD 1,737 | The ETF bought 75 new shares of PCRX (Pacira BioSciences, Inc.). The shares were bought for an average price of 23.16 compared to the previous average buy price of 23.8672. This is -3.0% lower than average price of previous purchases of PCRX. |
| GRFS - Grifols SA ADR | BUY | 204 @ USD 8.36 | USD 1,705 | The ETF bought 204 new shares of GRFS (Grifols SA ADR). The shares were bought for an average price of 8.36 compared to the previous average buy price of 9.33311. This is -10.4% lower than average price of previous purchases of GRFS. |
| EYPT - Eyepoint Pharmaceuticals Inc | BUY | 115 @ USD 14.4 | USD 1,656 | The ETF bought 115 new shares of EYPT (Eyepoint Pharmaceuticals Inc). The shares were bought for an average price of 14.4 compared to the previous average buy price of 8.94731. This is 60.9% higher than average price of previous purchases of EYPT. |
| ZLAB - Zai Lab Ltd | BUY | 80 @ USD 19.93 | USD 1,594 | The ETF bought 80 new shares of ZLAB (Zai Lab Ltd). The shares were bought for an average price of 19.93 compared to the previous average buy price of 33.4138. This is -40.4% lower than average price of previous purchases of ZLAB. |
| SANA - Sana Biotechnology Inc | BUY | 441 @ USD 3.54 | USD 1,561 | The ETF bought 441 new shares of SANA (Sana Biotechnology Inc). The shares were bought for an average price of 3.54 compared to the previous average buy price of 3.18395. This is 11.2% higher than average price of previous purchases of SANA. |
| TBPH - Theravance Biopharma Inc | BUY | 84 @ USD 18.5 | USD 1,554 | The ETF bought 84 new shares of TBPH (Theravance Biopharma Inc). The shares were bought for an average price of 18.5 compared to the previous average buy price of 12.0971. This is 52.9% higher than average price of previous purchases of TBPH. |
| MNMD - Mind Medicine Inc | BUY | 130 @ USD 11.75 | USD 1,528 | The ETF bought 130 new shares of MNMD (Mind Medicine Inc). The shares were bought for an average price of 11.75 compared to the previous average buy price of 8.72547. This is 34.7% higher than average price of previous purchases of MNMD. |
| NTLA - Intellia Therapeutics Inc | BUY | 182 @ USD 8.35 | USD 1,520 | The ETF bought 182 new shares of NTLA (Intellia Therapeutics Inc). The shares were bought for an average price of 8.35 compared to the previous average buy price of 12.219. This is -31.7% lower than average price of previous purchases of NTLA. |
| DAWN - Day One Biopharmaceuticals Inc | BUY | 171 @ USD 8.87999 | USD 1,518 | The ETF bought 171 new shares of DAWN (Day One Biopharmaceuticals Inc). The shares were bought for an average price of 8.87999 compared to the previous average buy price of 7.49873. This is 18.4% higher than average price of previous purchases of DAWN. |
| SVRA - Savara Inc | BUY | 289 @ USD 5.21 | USD 1,506 | The ETF bought 289 new shares of SVRA (Savara Inc). The shares were bought for an average price of 5.21 compared to the previous average buy price of 2.90352. This is 79.4% higher than average price of previous purchases of SVRA. |
| IOVA - Iovance Biotherapeutics Inc | BUY | 597 @ USD 2.5 | USD 1,493 | The ETF bought 597 new shares of IOVA (Iovance Biotherapeutics Inc). The shares were bought for an average price of 2.5 compared to the previous average buy price of 2.43568. This is 2.6% higher than average price of previous purchases of IOVA. |
| ERAS - Erasca Inc | BUY | 510 @ USD 2.89 | USD 1,474 | The ETF bought 510 new shares of ERAS (Erasca Inc). The shares were bought for an average price of 2.89 compared to the previous average buy price of 1.71936. This is 68.1% higher than average price of previous purchases of ERAS. |
| PAHC - Phibro Animal Health Corporation | BUY | 33 @ USD 43.08 | USD 1,422 | The ETF bought 33 new shares of PAHC (Phibro Animal Health Corporation). The shares were bought for an average price of 43.08 compared to the previous average buy price of 29.1877. This is 47.6% higher than average price of previous purchases of PAHC. |
| VIR - Vir Biotechnology Inc | BUY | 232 @ USD 6.12 | USD 1,420 | The ETF bought 232 new shares of VIR (Vir Biotechnology Inc). The shares were bought for an average price of 6.12 compared to the previous average buy price of 5.82261. This is 5.1% higher than average price of previous purchases of VIR. |
| VIR - Vidrala S.A | BUY | 232 @ USD 6.12 | USD 1,420 | The ETF bought 232 new shares of VIR (Vidrala S.A). The shares were bought for an average price of 6.12 compared to the previous average buy price of 5.82261. This is 5.1% higher than average price of previous purchases of VIR. |
| ARVN - Arvinas Inc | BUY | 120 @ USD 11.77 | USD 1,412 | The ETF bought 120 new shares of ARVN (Arvinas Inc). The shares were bought for an average price of 11.77 compared to the previous average buy price of 8.93005. This is 31.8% higher than average price of previous purchases of ARVN. |
| ABUS - Arbutus Biopharma Corp | BUY | 328 @ USD 4.27 | USD 1,401 | The ETF bought 328 new shares of ABUS (Arbutus Biopharma Corp). The shares were bought for an average price of 4.27 compared to the previous average buy price of 3.69328. This is 15.6% higher than average price of previous purchases of ABUS. |
| PACB - Pacific Biosciences of California | BUY | 535 @ USD 2.5 | USD 1,338 | The ETF bought 535 new shares of PACB (Pacific Biosciences of California). The shares were bought for an average price of 2.5 compared to the previous average buy price of 1.55289. This is 61.0% higher than average price of previous purchases of PACB. |
| SPRY - Silverback Therapeutics Inc | BUY | 165 @ USD 8.03001 | USD 1,325 | The ETF bought 165 new shares of SPRY (Silverback Therapeutics Inc). The shares were bought for an average price of 8.03001 compared to the previous average buy price of 13.2885. This is -39.6% lower than average price of previous purchases of SPRY. |
| REPL - Replimune Group Inc | BUY | 135 @ USD 9.39001 | USD 1,268 | The ETF bought 135 new shares of REPL (Replimune Group Inc). The shares were bought for an average price of 9.39001 compared to the previous average buy price of 8.92753. This is 5.2% higher than average price of previous purchases of REPL. |
| GERN - Geron Corporation | BUY | 1,067 @ USD 1.16 | USD 1,238 | The ETF bought 1067 new shares of GERN (Geron Corporation). The shares were bought for an average price of 1.16 compared to the previous average buy price of 1.50116. This is -22.7% lower than average price of previous purchases of GERN. |
| KROS - Keros Therapeutics Inc | BUY | 67 @ USD 17.01 | USD 1,140 | The ETF bought 67 new shares of KROS (Keros Therapeutics Inc). The shares were bought for an average price of 17.01 compared to the previous average buy price of 13.9207. This is 22.2% higher than average price of previous purchases of KROS. |
| PRME - Prime Medicine, Inc. Common Stock | BUY | 296 @ USD 3.79 | USD 1,122 | The ETF bought 296 new shares of PRME (Prime Medicine, Inc. Common Stock). The shares were bought for an average price of 3.79 compared to the previous average buy price of 3.9425. This is -3.9% lower than average price of previous purchases of PRME. |
| KALV - Kalvista Pharmaceuticals Inc | BUY | 83 @ USD 13.36 | USD 1,109 | The ETF bought 83 new shares of KALV (Kalvista Pharmaceuticals Inc). The shares were bought for an average price of 13.36 compared to the previous average buy price of 12.3674. This is 8.0% higher than average price of previous purchases of KALV. |
| RGNX - Regenxbio Inc | BUY | 89 @ USD 12.23 | USD 1,088 | The ETF bought 89 new shares of RGNX (Regenxbio Inc). The shares were bought for an average price of 12.23 compared to the previous average buy price of 9.27637. This is 31.8% higher than average price of previous purchases of RGNX. |
| MGTX - MeiraGTx Holdings PLC | BUY | 136 @ USD 7.57 | USD 1,030 | The ETF bought 136 new shares of MGTX (MeiraGTx Holdings PLC). The shares were bought for an average price of 7.57 compared to the previous average buy price of 7.21543. This is 4.9% higher than average price of previous purchases of MGTX. |
| MRVI - Maravai Lifesciences Holdings Inc | BUY | 265 @ USD 3.68 | USD 975 | The ETF bought 265 new shares of MRVI (Maravai Lifesciences Holdings Inc). The shares were bought for an average price of 3.68 compared to the previous average buy price of 2.74945. This is 33.8% higher than average price of previous purchases of MRVI. |
| PRTA - Prothena Corporation plc | BUY | 93 @ USD 10.4 | USD 967 | The ETF bought 93 new shares of PRTA (Prothena Corporation plc). The shares were bought for an average price of 10.4 compared to the previous average buy price of 9.13194. This is 13.9% higher than average price of previous purchases of PRTA. |
| FDMT - 4D Molecular Therapeutics Inc | BUY | 85 @ USD 10.89 | USD 926 | The ETF bought 85 new shares of FDMT (4D Molecular Therapeutics Inc). The shares were bought for an average price of 10.89 compared to the previous average buy price of 6.64661. This is 63.8% higher than average price of previous purchases of FDMT. |
| LXRX - Lexicon Pharmaceuticals Inc | BUY | 645 @ USD 1.42 | USD 916 | The ETF bought 645 new shares of LXRX (Lexicon Pharmaceuticals Inc). The shares were bought for an average price of 1.42 compared to the previous average buy price of 1.07887. This is 31.6% higher than average price of previous purchases of LXRX. |
| IRWD - Ironwood Pharmaceuticals Inc | BUY | 261 @ USD 3.32 | USD 867 | The ETF bought 261 new shares of IRWD (Ironwood Pharmaceuticals Inc). The shares were bought for an average price of 3.32 compared to the previous average buy price of 1.31297. This is 152.9% higher than average price of previous purchases of IRWD. |
| EOLS - Evolus Inc | BUY | 119 @ USD 6.74 | USD 802 | The ETF bought 119 new shares of EOLS (Evolus Inc). The shares were bought for an average price of 6.74 compared to the previous average buy price of 9.08616. This is -25.8% lower than average price of previous purchases of EOLS. |
| GLPG - Galapagos NV ADR | BUY | 25 @ USD 31.0501 | USD 776 | The ETF bought 25 new shares of GLPG (Galapagos NV ADR). The shares were bought for an average price of 31.0501 compared to the previous average buy price of 29.1327. This is 6.6% higher than average price of previous purchases of GLPG. |
| GLPG - Galapagos N.V. | BUY | 25 @ USD 31.0501 | USD 776 | The ETF bought 25 new shares of GLPG (Galapagos N.V.). The shares were bought for an average price of 31.0501 compared to the previous average buy price of 29.1327. This is 6.6% higher than average price of previous purchases of GLPG. |
| HCM - HUTCHMED China Ltd | BUY | 54 @ USD 14.22 | USD 768 | The ETF bought 54 new shares of HCM (HUTCHMED China Ltd). The shares were bought for an average price of 14.22 compared to the previous average buy price of 15.387. This is -7.6% lower than average price of previous purchases of HCM. |
| HCM - Hitachi Construction Machinery Co. Ltd | BUY | 54 @ USD 14.22 | USD 768 | The ETF bought 54 new shares of HCM (Hitachi Construction Machinery Co. Ltd). The shares were bought for an average price of 14.22 compared to the previous average buy price of 15.387. This is -7.6% lower than average price of previous purchases of HCM. |
| LYEL - Lyell Immunopharma Inc | BUY | 33 @ USD 22.72 | USD 750 | The ETF bought 33 new shares of LYEL (Lyell Immunopharma Inc). The shares were bought for an average price of 22.72 compared to the previous average buy price of 4.48207. This is 406.9% higher than average price of previous purchases of LYEL. |
| ALT - Altitude Group Plc | BUY | 146 @ USD 5.1 | USD 745 | The ETF bought 146 new shares of ALT (Altitude Group Plc). The shares were bought for an average price of 5.1 compared to the previous average buy price of 5.22388. This is -2.4% lower than average price of previous purchases of ALT. |
| SIGA - SIGA Technologies Inc | BUY | 121 @ USD 5.94 | USD 719 | The ETF bought 121 new shares of SIGA (SIGA Technologies Inc). The shares were bought for an average price of 5.94 compared to the previous average buy price of 6.76898. This is -12.2% lower than average price of previous purchases of SIGA. |
| TRDA - Entrada Therapeutics Inc | BUY | 70 @ USD 9.88999 | USD 692 | The ETF bought 70 new shares of TRDA (Entrada Therapeutics Inc). The shares were bought for an average price of 9.88999 compared to the previous average buy price of 7.7192. This is 28.1% higher than average price of previous purchases of TRDA. |
| RCKT - Rocket Pharmaceuticals Inc | BUY | 184 @ USD 3.03 | USD 558 | The ETF bought 184 new shares of RCKT (Rocket Pharmaceuticals Inc). The shares were bought for an average price of 3.03 compared to the previous average buy price of 5.0663. This is -40.2% lower than average price of previous purchases of RCKT. |
| BCYC - Bicycle Therapeutics Ltd | BUY | 81 @ USD 6.73999 | USD 546 | The ETF bought 81 new shares of BCYC (Bicycle Therapeutics Ltd). The shares were bought for an average price of 6.73999 compared to the previous average buy price of 8.45791. This is -20.3% lower than average price of previous purchases of BCYC. |
| VNDA - Vanda Pharmaceuticals Inc | BUY | 111 @ USD 4.89001 | USD 543 | The ETF bought 111 new shares of VNDA (Vanda Pharmaceuticals Inc). The shares were bought for an average price of 4.89001 compared to the previous average buy price of 4.85551. This is 0.7% higher than average price of previous purchases of VNDA. |
| ACIU - AC Immune Ltd | BUY | 173 @ USD 3.08 | USD 533 | The ETF bought 173 new shares of ACIU (AC Immune Ltd). The shares were bought for an average price of 3.08 compared to the previous average buy price of 2.45738. This is 25.3% higher than average price of previous purchases of ACIU. |
| ALLO - Allogene Therapeutics Inc | BUY | 380 @ USD 1.35 | USD 513 | The ETF bought 380 new shares of ALLO (Allogene Therapeutics Inc). The shares were bought for an average price of 1.35 compared to the previous average buy price of 1.33296. This is 1.3% higher than average price of previous purchases of ALLO. |
| AUTL - Autolus Therapeutics Ltd | BUY | 376 @ USD 1.24 | USD 466 | The ETF bought 376 new shares of AUTL (Autolus Therapeutics Ltd). The shares were bought for an average price of 1.24 compared to the previous average buy price of 1.80548. This is -31.3% lower than average price of previous purchases of AUTL. |
| AVXL - Anavex Life Sciences Corp | BUY | 149 @ USD 3.08 | USD 459 | The ETF bought 149 new shares of AVXL (Anavex Life Sciences Corp). The shares were bought for an average price of 3.08 compared to the previous average buy price of 9.1684. This is -66.4% lower than average price of previous purchases of AVXL. |
| AVIR - Atea Pharmaceuticals Inc | BUY | 144 @ USD 2.98 | USD 429 | The ETF bought 144 new shares of AVIR (Atea Pharmaceuticals Inc). The shares were bought for an average price of 2.98 compared to the previous average buy price of 3.3071. This is -9.9% lower than average price of previous purchases of AVIR. |
| EDIT - Editas Medicine Inc | BUY | 165 @ USD 2.50001 | USD 413 | The ETF bought 165 new shares of EDIT (Editas Medicine Inc). The shares were bought for an average price of 2.50001 compared to the previous average buy price of 2.73397. This is -8.6% lower than average price of previous purchases of EDIT. |
| OABI - OmniAb Inc. | BUY | 214 @ USD 1.73001 | USD 370 | The ETF bought 214 new shares of OABI (OmniAb Inc.). The shares were bought for an average price of 1.73001 compared to the previous average buy price of 1.88851. This is -8.4% lower than average price of previous purchases of OABI. |
| VYGR - Voyager Therapeutics Inc | BUY | 89 @ USD 4.1 | USD 365 | The ETF bought 89 new shares of VYGR (Voyager Therapeutics Inc). The shares were bought for an average price of 4.1 compared to the previous average buy price of 3.88733. This is 5.5% higher than average price of previous purchases of VYGR. |
| HUMA - Humacyte Inc | BUY | 281 @ USD 1.28 | USD 360 | The ETF bought 281 new shares of HUMA (Humacyte Inc). The shares were bought for an average price of 1.28 compared to the previous average buy price of 2.16249. This is -40.8% lower than average price of previous purchases of HUMA. |
| ARCT - Arcturus Therapeutics Holdings Inc | BUY | 49 @ USD 6.32999 | USD 310 | The ETF bought 49 new shares of ARCT (Arcturus Therapeutics Holdings Inc). The shares were bought for an average price of 6.32999 compared to the previous average buy price of 14.2503. This is -55.6% lower than average price of previous purchases of ARCT. |
| MXCT - MaxCyte Inc | BUY | 185 @ USD 1.67 | USD 309 | The ETF bought 185 new shares of MXCT (MaxCyte Inc). The shares were bought for an average price of 1.67 compared to the previous average buy price of 2.14764. This is -22.2% lower than average price of previous purchases of MXCT. |
| ALEC - Alector Inc | BUY | 183 @ USD 1.28 | USD 234 | The ETF bought 183 new shares of ALEC (Alector Inc). The shares were bought for an average price of 1.28 compared to the previous average buy price of 1.89408. This is -32.4% lower than average price of previous purchases of ALEC. |
| MRSN - Mersana Therapeutics Inc | BUY | 8 @ USD 27.3899 | USD 219 | The ETF bought 8 new shares of MRSN (Mersana Therapeutics Inc). The shares were bought for an average price of 27.3899 compared to the previous average buy price of 0.66826. This is 3,998.7% higher than average price of previous purchases of MRSN. |
| FATE - Fate Therapeutics Inc | BUY | 189 @ USD 1.08001 | USD 204 | The ETF bought 189 new shares of FATE (Fate Therapeutics Inc). The shares were bought for an average price of 1.08001 compared to the previous average buy price of 1.17883. This is -8.4% lower than average price of previous purchases of FATE. |
| PLRX - Pliant Therapeutics Inc | BUY | 100 @ USD 1.56999 | USD 157 | The ETF bought 100 new shares of PLRX (Pliant Therapeutics Inc). The shares were bought for an average price of 1.56999 compared to the previous average buy price of 1.50677. This is 4.2% higher than average price of previous purchases of PLRX. |
| MGNX - MacroGenics Inc | BUY | 107 @ USD 1.41999 | USD 152 | The ETF bought 107 new shares of MGNX (MacroGenics Inc). The shares were bought for an average price of 1.41999 compared to the previous average buy price of 1.57467. This is -9.8% lower than average price of previous purchases of MGNX. |
| BMEA - Biomea Fusion Inc | BUY | 119 @ USD 1.01 | USD 120 | The ETF bought 119 new shares of BMEA (Biomea Fusion Inc). The shares were bought for an average price of 1.01 compared to the previous average buy price of 1.74139. This is -42.0% lower than average price of previous purchases of BMEA. |
| STRO - Sutro Biopharma | BUY | 136 @ USD 0.875 | USD 119 | The ETF bought 136 new shares of STRO (Sutro Biopharma). The shares were bought for an average price of 0.875 compared to the previous average buy price of 0.901682. This is -3.0% lower than average price of previous purchases of STRO. |
| OKUR - OKUR | BUY | 21 @ USD 2.74997 | USD 58 | The ETF bought 21 new shares of OKUR (OKUR). The shares were bought for an average price of 2.74997 compared to the previous average buy price of 6.06237. This is -54.6% lower than average price of previous purchases of OKUR. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| CGEM - Cullinan Oncology LLC | HOLD | 0 @ USD 12.93 | USD 0 | The current share valuation price of CGEM based on adjusted close was USD 12.93. The average price that CGEM shares were previous bought at was USD 7.90946. The current market price is 63.5% higher than average price they were purchased at. The value of the holding in CGEM has increased by USD 138,448 compared to the previous valuation of Cullinan Oncology LLC however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| RLAY - Relay Therapeutics Inc | HOLD | 0 @ USD 8.17 | USD 0 | The current share valuation price of RLAY based on adjusted close was USD 8.17. The average price that RLAY shares were previous bought at was USD 4.25515. The current market price is 92.0% higher than average price they were purchased at. The value of the holding in RLAY has increased by USD 157,931 compared to the previous valuation of Relay Therapeutics Inc however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.04749. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2025-11-24 this would crystalise an overall loss. |